Terazosin-md

Overview

Terazosin -md (compound TZ-md), a derivative of both Alfuzosin ( HY-B0192 ) and Terazosin ( HY-B0371 ), is an orally active α1-adrenergic receptor antagonist. Terazosin -md has the functions of improving mitochondrial metabolism , degrading various pathological protein accumulations and improving the function of vascular endothelial cells. Terazosin -md shows effect in a mouse model with Alzheimer's disease. Terazosin -md can be used for research in Alzheimer's disease and related complications, and diseases associated with protein accumulation and metabolic disorders.

Application

Products | Products > Disease Areas > Depression | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Huntington's Disease | Products > Disease Areas > Amyotrophic Lateral Sclerosis | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Adrenergic Receptor | Products > Signaling Pathways > Mitochondrial Metabolism

Product Information

• Catalog No.: HY-128613
• CAS No.: 2423919-77-9
• Molecular Formula: C20H26N4O4
• Molecular Weight: 386.44
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source